High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa - 14/04/20
Abstract |
Background |
The permanent disfigurement associated with hidradenitis suppurativa (HS) necessitates early aggressive disease intervention. Although limited data support the use of infliximab (IFX) in HS, the efficacy of high-dose, high-frequency IFX has yet to be defined.
Objective |
To evaluate the efficacy of IFX 7.5 to 10 mg/kg, with a maintenance frequency every 4 weeks.
Methods |
Prospective analysis of 42 patients initiating IFX 7.5 mg/kg every 4 weeks (IFX 7.5) and 16 patients receiving dose escalation to IFX 10 mg/kg every 4 weeks (IFX 10) between March 1, 2018, and February 28, 2019. The primary outcome measure (clinical response) was the proportion of patients with Physician Global Assessment of clear, minimal, or mild (score of 0-2) HS with at least a 2-grade improvement from baseline scores.
Results |
The proportion of patients achieving a clinical response after initiating IFX 7.5 was 20 of 42 (47.6%) at week 4 and 17 of 24 (70.8%) at week 12. For patients receiving dose escalation to IFX 10 because of incomplete initial response, 6 of 16 (37.5%) achieved clinical response at week 4 and 6 of 12 (50%) at week 12.
Conclusions |
Initiation of IFX 7.5 every 4 weeks, with possible dose escalation to IFX 10, if needed, provides optimal mitigation of HS-related disease activity.
Le texte complet de cet article est disponible en PDF.Key words : acne inversa, anti-TNF, anti–TNF-α therapy, biologics, hidradenitis, hidradenitis suppurativa, high dose, high frequency, infliximab, TNF inhibitor
Abbreviations used : BMI, HS, IBD, IFX, IFX 5, IFX 7.5, IFX 10, MCID, NRS, PGA, SAE
Plan
| Funding sources: Mr Johnston was supported by the Albert Einstein College of Medicine Medical Scientist Training Program (NIH NIGMS T32 GM007288). |
|
| Disclosure: Dr Cohen has served as principal investigator and on the advisory board for AbbVie, Inc, and on the advisory board for Verrica Pharmaceuticals. Ms Ghias, Mr Johnston, and Drs Kutner, Micheletti, and Hosgood have to conflicts of interest to declare. |
|
| IRB approval status: Reviewed and approved by the Albert Einstein College of Medicine/Montefiore Medical Center IRB (2015-5906). |
|
| Supplemental tables and figures available at 9mhhh2zjbb.2. |
Vol 82 - N° 5
P. 1094-1101 - mai 2020 Retour au numéro
Article précédent
- RAS pathway influences the number of melanocytic nevi in cardiofaciocutaneous and Costello syndromes
- Maija Kiuru, Jennifer Urban, Guannan Zhu, Iryna Rybak, Jessica R. Terrell, Lihong Qi, John D. McPherson, Ashfaq A. Marghoob, Katherine A. Rauen
- Age-dependent interaction between sex and geographic ultraviolet index in melanoma risk
- Feng Liu-Smith, Argyrios Ziogas
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?